HRP20171415T4 - Heterociklični spojevi za liječenje neuroloških i psiholoških poremećaja - Google Patents
Heterociklični spojevi za liječenje neuroloških i psiholoških poremećaja Download PDFInfo
- Publication number
- HRP20171415T4 HRP20171415T4 HRP20171415TT HRP20171415T HRP20171415T4 HR P20171415 T4 HRP20171415 T4 HR P20171415T4 HR P20171415T T HRP20171415T T HR P20171415TT HR P20171415 T HRP20171415 T HR P20171415T HR P20171415 T4 HRP20171415 T4 HR P20171415T4
- Authority
- HR
- Croatia
- Prior art keywords
- image
- optionally substituted
- compound
- compound according
- pharmaceutically acceptable
- Prior art date
Links
- 208000012902 Nervous system disease Diseases 0.000 title claims 2
- 230000000926 neurological effect Effects 0.000 title claims 2
- 208000020016 psychiatric disease Diseases 0.000 title claims 2
- 208000025966 Neurological disease Diseases 0.000 title 1
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 24
- 150000003839 salts Chemical class 0.000 claims 7
- 125000001931 aliphatic group Chemical group 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- 238000013268 sustained release Methods 0.000 claims 2
- 239000012730 sustained-release form Substances 0.000 claims 2
- 125000006686 (C1-C24) alkyl group Chemical group 0.000 claims 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000004688 alkyl sulfonyl alkyl group Chemical group 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 125000006350 alkyl thio alkyl group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000005110 aryl thio group Chemical group 0.000 claims 1
- 125000005164 aryl thioalkyl group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- -1 arylsulfonylalkyl Chemical group 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 125000003396 thiol group Chemical class [H]S* 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (18)
1. Spoj predstavljen formulom V:
[image]
ili njegovi geometrijski izomeri, enantiomeri, diastereomeri, racemati, farmaceutski prihvatljive soli i solvati navedenog,
gdje
[image]
predstavlja jednostruku ili dvostruku vezu;
w je 4;
R5 je izabran od -CH(R10)-OC(O)OR20, -CH(R10)-OC(O)R20, -CH(R10)-OC(O)NR20R21,
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
i
[image]
gdje z je 1, 2, 3, 4, 5, 6 ili 7;
svako R20 i R21 je neovisno izabrano od vodika, alifatika, supstituiranog alifatika, arila ili supstituiranog arila;
svako x i y je neovisno cijeli broj između 0 i 30,
gdje su R100, R101 i R103 neovisno izabrani od vodika, halogena, izborno supstituiranog C1-C8 alkila, izborno supstituiranog C2-C8 alkenila, izborno supstituiranog C2-C8 alkinila, izborno supstituiranog C3-C8 cikloalkila, izborno supstituiranog C1-C8 alkoksi, izborno supstituiranog C1-C8 alkilamino i izborno supstituiranog C1-C8 arila;
R105, R106 i R107 su neovisno izabrani od vodika, halogena, izborno supstituiranog C1-C24 alkila, izborno supstituiranog C2-C24 alkenila, izborno supstituiranog C2-C24 alkinila, izborno supstituiranog C3-C24 cikloalkila, izborno supstituiranog C1-C24 alkoksi, izborno supstituiranog C1-C24 alkilamino i izborno supstituiranog C1-C24 arila;
R10 je vodik, halogen, alifatik, supstituirani alifatik, aril ili supstituirani aril; i
gdje "supstituiran" označava zamjenu jednog ili više vodikovih radikala u danoj strukturi radikalom naznačenog supstituenta izabranog od halo, alkil, alkenil, alkinil, aril, heterociklil, tiol, alkiltio, ariltio, alkiltioalkil, ariltioalkil, alkilsulfonil, alkilsulfonilalkil, arilsulfonilalkil, alkoksi, ariloksi, aralkoksi, aminokarbonil, alkilaminokarbonil, arilaminokarbonil, alkoksikarbonil, ariloksikarbonil, haloalkil, amino, trifluorometil, cijano, nitro, alkilamino, arilamino, alkilaminoalkil, arilaminoalkil, aminoalkilamino, hidroksi, alkoksialkil, karboksialkil, alkoksikarbonilalkil, aminokarbonilalkil, acil, aralkoksikarbonil, karboksilne kiseline, sulfonske kiseline, sulfonila, fosfonske kiseline, heteroarila, heterociklika i alifatika.
2. Spoj prema patentnom zahtjevu 1, naznačen time što je R5 izabran od:
[image]
i
[image]
3. Spoj prema patentnom zahtjevu 1, naznačen time što je R5 izabran od:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
pri čemu, svaki x i y je neovisno cijeli broj između 0 i 30, i R105, R106 i R107 su kao što je definirano u patentnom zahtjevu 1.
4. Spoj prema patentnom zahtjevu 1, naznačen time što je R5 izabran iz tabele 1:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
5. Spoj prema patentnom zahtjevu 1, naznačen time što je R5 izabran iz tabele 2, 3 ili 4:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
6. Spoj prema patentnom zahtjevu 1, koji ima formulu:
[image]
ili
[image]
ili njihovi geometrijski izomeri, enantiomeri, diastereomeri, racemati, farmaceutski prihvatljive soli i solvati navedenog:
gdje je R5 izabran iz tabele 1:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
7. Spoj prema patentnom zahtjevu 1 izabran iz tabele A ili B i geometrijski izomeri, enantiomeri, diastereomeri, racemati, farmaceutski prihvatljive soli i solvati navedenog:
Tabela A
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
Tabela B
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
8. Spoj prema patentnom zahtjevu 1, formule:
[image]
ili njegova farmaceutski prihvatljiva sol.
9. Spoj prema patentnom zahtjevu 1, formule:
[image]
ili njegova farmaceutski prihvatljiva sol.
10. Spoj prema patentnom zahtjevu 1, formule:
[image]
ili njegova farmaceutski prihvatljiva sol.
11. Spoj prema patentnom zahtjevu 1, formule:
[image]
ili njegova farmaceutski prihvatljiva sol.
12. Spoj prema bilo kojem od patentnih zahtjeva 1-11 za uporabu u liječenju neurološkog ili psihijatrijskog poremećaja.
13. Spoj za upotrebu prema patentnom zahtjevu 12, naznačen time što je navedeni poremećaj shizofrenija.
14. Spoj prema bilo kojem od patentnih zahtjeva 1-11 za uporabu u postupku za produženu isporuku spoja formule XXIII-V:
[image]
gdje je w kao što je definirano u patentnom zahtjevu 1; pri čemu je, nakon primjene kod pacijenta, oslobađanje spoja formule XXIII-V produženo oslobađanje.
15. Spoj za uporabu prema patentnom zahtjevu 14, naznačen time što produženo oslobađanje obuhvaća terapeutski efikasnu količinu navedenog spoja formule XXIII-V u krvotoku pacijenta tijekom perioda od najmanje oko 36 sati nakon primjene spoja prema bilo kojem od patentnih zahtjeva 1 do 11.
16. Spoj za uporabu prema patentnom zahtjevu 14, naznačen time što je navedeni spoj formule XXIII-V prisutno u krvotoku pacijenta tijekom perioda odabranog od: najmanje 7, 15, 30, 60, 75 ili 90 dana.
17. Spoj za uporabu prema patentnom zahtjevu 16, naznačen time što se spoj primjenjuje injekcijom.
18. Farmaceutski pripravak koji sadrži terapeutski efikasnu količinu spoja prema bilo kojem od patentnih zahtjeva 1-11 i jedan ili više farmaceutski prihvatljivih nosača ili ekscipijenasa.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22048009P | 2009-06-25 | 2009-06-25 | |
| US29308710P | 2010-01-07 | 2010-01-07 | |
| PCT/US2010/039855 WO2010151689A1 (en) | 2009-06-25 | 2010-06-24 | Heterocyclic compounds for the treatment of neurological and psychological disorders |
| EP10792677.6A EP2445502B2 (en) | 2009-06-25 | 2010-06-24 | Heterocyclic compounds for the treatment of neurological and psychological disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20171415T1 HRP20171415T1 (hr) | 2017-12-15 |
| HRP20171415T4 true HRP20171415T4 (hr) | 2023-03-03 |
Family
ID=43386893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171415TT HRP20171415T4 (hr) | 2009-06-25 | 2010-06-24 | Heterociklični spojevi za liječenje neuroloških i psiholoških poremećaja |
Country Status (20)
| Country | Link |
|---|---|
| US (11) | US8431576B2 (hr) |
| EP (3) | EP4124616A1 (hr) |
| JP (4) | JP5733841B2 (hr) |
| AU (1) | AU2010266018B2 (hr) |
| CA (1) | CA2766088C (hr) |
| CY (1) | CY1120054T1 (hr) |
| DK (1) | DK2445502T4 (hr) |
| ES (2) | ES3031438T3 (hr) |
| FI (1) | FI2445502T4 (hr) |
| HK (1) | HK1253046A1 (hr) |
| HR (1) | HRP20171415T4 (hr) |
| HU (1) | HUE033442T2 (hr) |
| LT (1) | LT2445502T (hr) |
| NZ (1) | NZ597107A (hr) |
| PL (1) | PL2445502T5 (hr) |
| PT (1) | PT2445502T (hr) |
| RS (1) | RS56352B2 (hr) |
| SI (1) | SI2445502T1 (hr) |
| SM (1) | SMT201700430T1 (hr) |
| WO (1) | WO2010151689A1 (hr) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010151689A1 (en) | 2009-06-25 | 2010-12-29 | Alkermes, Inc. | Heterocyclic compounds for the treatment of neurological and psychological disorders |
| AU2010266040B2 (en) * | 2009-06-25 | 2015-01-15 | Alkermes Pharma Ireland Limited | Prodrugs of NH-acidic compounds |
| WO2011084851A1 (en) * | 2010-01-07 | 2011-07-14 | Alkermes, Inc. | Asenapine produrugs |
| ES2647361T3 (es) | 2010-01-07 | 2017-12-21 | Alkermes Pharma Ireland Limited | Profármacos de sales de amonio cuaternario |
| EP2521545B1 (en) | 2010-01-07 | 2019-11-27 | Alkermes Pharma Ireland Limited | Prodrugs of heteroaromatic compounds |
| US20110166156A1 (en) * | 2010-01-07 | 2011-07-07 | Alkermes, Inc. | Prodrugs for the Treatment of Schizophrenia and Bipolar Disease |
| US20110166128A1 (en) * | 2010-01-07 | 2011-07-07 | Alkermes, Inc. | Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders |
| CA2797708C (en) * | 2010-05-04 | 2016-08-16 | Alkermes Pharma Ireland Limited | Process for synthesizing oxidized lactam compounds |
| EP2585066B1 (en) | 2010-06-24 | 2018-09-26 | Alkermes Pharma Ireland Limited | Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
| EP2608670B1 (en) | 2010-08-23 | 2018-10-31 | Alkermes Pharma Ireland Limited | Methods for treating antipsychotic-induced weight gain |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| ES2661574T3 (es) * | 2010-12-23 | 2018-04-02 | Alkermes Pharma Ireland Limited | Profármacos de carga de múltiples PAF |
| LT2685979T (lt) * | 2011-03-18 | 2016-12-12 | Alkermes Pharma Ireland Limited | Injekcinės farmacinės kompozicijos, apimančios vandenyje netirpų antipsichotiką, sorbitano lauratą ir polisorbatą 20 |
| JO3227B1 (ar) | 2011-09-08 | 2018-03-08 | Otsuka Pharma Co Ltd | مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان |
| UA108713C2 (xx) | 2011-11-11 | 2015-05-25 | 2-тіопіримідинони | |
| ES2715562T3 (es) | 2011-12-15 | 2019-06-04 | Alkermes Pharma Ireland Ltd | Profármacos de compuestos de amina secundaria |
| NZ630703A (en) | 2012-03-19 | 2017-02-24 | Alkermes Pharma Ireland Ltd | Pharmaceutical compositions comprising glycerol esters |
| EP2827866B1 (en) | 2012-03-19 | 2023-05-03 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising benzyl alcohol |
| NZ630643A (en) | 2012-03-19 | 2017-08-25 | Alkermes Pharma Ireland Ltd | Pharmaceutical compositions comprising fatty acid esters |
| PT3495367T (pt) | 2012-06-13 | 2020-11-12 | Incyte Holdings Corp | Compostos tricíclicos substituídos como inibidores de fgfr |
| SI2861608T1 (sl) | 2012-06-19 | 2019-08-30 | Debiopharm International Sa | Derivati predzdravila (E)-N-metil-N-((3-metilbenzofuran-2-IL)metil)- 3-(7-okso-5,6,7,8-tetrahidro-1 ,8-nafthiridin-3-il)akrilamid |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| WO2014080285A2 (en) | 2012-09-19 | 2014-05-30 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions having improved storage stability |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| JP2014196292A (ja) * | 2013-03-07 | 2014-10-16 | 大塚製薬株式会社 | 医薬 |
| MX393494B (es) | 2013-04-19 | 2025-03-24 | Incyte Holdings Corp | Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr). |
| US10525057B2 (en) | 2013-09-24 | 2020-01-07 | Otsuka Pharmaceutical Co., Ltd. | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
| CN106132415A (zh) | 2014-03-20 | 2016-11-16 | 奥克梅斯制药爱尔兰有限公司 | 具有增加的注射速度的阿立哌唑制剂 |
| US10016415B2 (en) | 2014-08-18 | 2018-07-10 | Alkermes Pharma Ireland Limited | Aripiprazole prodrug compositions |
| PL3508196T3 (pl) | 2014-08-18 | 2021-12-20 | Alkermes Pharma Ireland Limited | Kompozycje proleku arypiprazolu |
| MA40480B1 (fr) * | 2014-08-25 | 2021-08-31 | Alkermes Pharma Ireland Ltd | Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| CR20170390A (es) | 2015-02-20 | 2017-10-23 | Incyte Holdings Corp | Heterociclos biciclicos como inhibidores de fgfr |
| MX382097B (es) | 2015-05-05 | 2025-03-13 | Pfizer | 1-(2-aminoetil)-6-(2-(2-hidroxietoxi)-5-metilfenil)-2-tioxo-2,3-dihidropirimidin-4(1h)-ona, y el uso del mismo para tratar afecciones cardiovasculares. |
| ES2893973T3 (es) | 2016-02-17 | 2022-02-10 | Alkermes Pharma Ireland Ltd | Composiciones de múltiples profármacos de aripiprazol |
| CA3014541A1 (en) | 2016-02-26 | 2017-08-31 | Debiopharm International S.A. | Medicament for treatment of diabetic foot infections |
| WO2018104953A1 (en) * | 2016-12-07 | 2018-06-14 | Msn Laboratories Private Limited, R&D Center | Improved process for the preparation of 7-{4-[4-(2,3-dichlorophenyl)-piperazin-1-yl]butoxy}-2oxo-3,4-dihydro-2h-quinolin-1-yl)methyl dodecanoate |
| US10815216B2 (en) * | 2016-12-14 | 2020-10-27 | Neuland Pharma Research Private Limited | Process for the preparation of aripiprazole lauroxil |
| US20180265472A1 (en) * | 2017-03-17 | 2018-09-20 | Scinopharm Taiwan, Ltd. | Process for preparing aripiprazole lauroxil and intermediates thereof |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| CN111315722B (zh) * | 2017-07-28 | 2023-06-16 | 因特奎姆私人控股公司 | 制备月桂酰阿立哌唑的方法 |
| CN107628999B (zh) * | 2017-10-25 | 2019-07-02 | 苏州华健瑞达医药技术有限公司 | 阿立哌唑十二烷酸酯的制备方法 |
| CN110218209B (zh) * | 2018-03-02 | 2022-09-30 | 上海现代药物制剂工程研究中心有限公司 | 一种依匹哌唑月桂酸酯的晶型a、其制备方法及应用 |
| CN112423754A (zh) | 2018-03-05 | 2021-02-26 | 奥克梅斯制药爱尔兰有限公司 | 阿立哌唑的给药策略 |
| WO2019213544A2 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
| US11174257B2 (en) | 2018-05-04 | 2021-11-16 | Incyte Corporation | Salts of an FGFR inhibitor |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021009087A1 (en) | 2019-07-12 | 2021-01-21 | Interquim, S.A. | Process for the preparation of aripiprazole lauroxil |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076602A1 (en) | 2019-10-14 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| PE20221504A1 (es) | 2019-12-04 | 2022-09-30 | Incyte Corp | Derivados de un inhibidor de fgfr |
| JP2023505258A (ja) | 2019-12-04 | 2023-02-08 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式複素環 |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2022101444A1 (en) | 2020-11-12 | 2022-05-19 | Alkermes Pharma Ireland Limited | Immediate release multilayer tablet |
| CN112656761B (zh) * | 2020-12-30 | 2023-09-08 | 河南合智医药科技有限公司 | 一种低刺激性阿立哌唑前药的油溶缓释注射制剂及其制备方法 |
| TW202304459A (zh) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法 |
| CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2024039599A1 (en) | 2022-08-17 | 2024-02-22 | Transcend Therapeutics, Inc. | Phenethylamines and cathinones precursors |
| CN118121699A (zh) * | 2022-12-02 | 2024-06-04 | 上海日馨医药科技股份有限公司 | Tpk激动剂及使用其治疗神经退行性疾病的方法 |
| TW202448427A (zh) * | 2023-05-02 | 2024-12-16 | 日商大塚製藥股份有限公司 | 雜環化合物及其用途 |
Family Cites Families (135)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5006A (en) | 1847-03-06 | Improvement in the process of manufacturing wire grating | ||
| US528A (en) | 1837-12-20 | Improvement in cooking-stoves | ||
| US2418499A (en) | 1944-06-20 | 1947-04-08 | Du Pont | 2-alkoxymethylmercapto-thiazoles and thiazolines and a process for preparing the same |
| DE1070760B (de) * | 1955-11-19 | 1959-12-10 | Badische Anilin- S- Soda-Fabrik Aktiengesellschaft, Ludwigshafen / Rhein | Verfahren zur Herstellung von Azofarbstoffen |
| GB849541A (en) | 1956-02-23 | 1960-09-28 | Rohm & Haas | Preparation of unsaturated cyclic urea derivatives |
| DE1273533B (de) | 1962-09-08 | 1968-07-25 | Hoechst Ag | Verfahren zur Herstellung von N-(ª‡-Alkoxy-alkyl)-carbonsaeureamiden |
| US3452034A (en) | 1967-03-09 | 1969-06-24 | American Cyanamid Co | Substituted 2-(1,3,4-thiadiazol-2-yl)-4(5)-nitroimidazoles |
| US3573308A (en) * | 1969-04-03 | 1971-03-30 | Hoffmann La Roche | 3-lower alkoxy methyl-3,4-dihydro-4-hydroxy-4-aryl quinazolin-2(1h) ones and related compounds |
| US3957808A (en) | 1969-09-03 | 1976-05-18 | Rohm And Haas Company | 3-alkoxyisothiazoles |
| US3998815A (en) * | 1974-06-24 | 1976-12-21 | Interx Research Corporation | 1-hydrocarbonoyloxymethyl-3-carbamoyl or 3-carboethoxy-pyridinium salts |
| US4204065A (en) * | 1975-09-22 | 1980-05-20 | Interx Research Corporation | Soft quaternary surface active agents and method of using same |
| JPS5331676A (en) | 1976-09-06 | 1978-03-25 | Mitsui Toatsu Chem Inc | Uracil derivatives and their preparation |
| US4260769A (en) * | 1977-04-22 | 1981-04-07 | Interx Research Corporation | 5,5-Diphenylhydantoins |
| JPS54130587A (en) | 1978-03-30 | 1979-10-09 | Otsuka Pharmaceut Co Ltd | Carbostyryl derivative |
| EP0005828B1 (de) | 1978-06-06 | 1981-03-11 | Hoechst Aktiengesellschaft | Neue substituierte Phenylpiperazinderivate, diese enthaltende Arzneimittel und Verfahren zu deren Herstellung |
| FI77852C (fi) | 1981-02-17 | 1989-05-10 | Otsuka Pharma Co Ltd | Foerfarande foer framstaellning av nya, saosom hjaertmediciner anvaendbara substituerade amid- och (maettad heterocykel)karbonylkarbostyrilderivat. |
| AU532361B2 (en) | 1981-09-01 | 1983-09-29 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| DE3149010A1 (de) | 1981-12-10 | 1983-07-07 | A. Nattermann & Cie GmbH, 5000 Köln | (+)-2-(1-(2,6-dichlorphenoxy)-ethyl)-1,3- diazacyclopent-2-en, dessen herstellung und seine verwendung in pharamazeutischen praeparaten |
| US4428935A (en) * | 1982-05-24 | 1984-01-31 | Pfizer Inc. | Penicillanic acid dioxide prodrug |
| IT1212743B (it) * | 1983-05-17 | 1989-11-30 | Dompe Farmaceutici Spa | Sali quaternari di derivati di benzo[ 1,4 ]diazepinonici,pirido [1,4]benzodiazepinonici,prido [1,5]benzodiazepinonici e loro atti vita' farmacologica |
| US4760057A (en) * | 1983-06-23 | 1988-07-26 | Merck & Co., Inc. | (Acyloxyalkoxy)carbonyl derivatives as bioreversible prodrug moieties for primary and secondary amine functions in drugs |
| DE3544134A1 (de) | 1984-12-15 | 1986-06-19 | Mitsubishi Chemical Industries Ltd., Tokio/Tokyo | Verfahren zur herstellung von n-((alpha)-alkoxyethyl) pyrrolidon |
| JPS61171467A (ja) | 1985-01-23 | 1986-08-02 | Mitsubishi Chem Ind Ltd | Ｎ−（α−アルコキシエチル）ピロリドンの製造方法 |
| AR240698A1 (es) | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
| GB8513754D0 (en) * | 1985-05-31 | 1985-07-03 | Jones T R | Anti-cancer quinazoline derivatives |
| FR2587029B1 (fr) | 1985-09-11 | 1987-10-30 | Synthelabo | Derives de benzimidazole, leur preparation et leur application en therapeutique |
| DK588486A (da) * | 1985-12-09 | 1987-06-10 | Otsuka Pharma Co Ltd | Anvendelse af en forbindelse til behandling af hypoxi |
| GB8607683D0 (en) * | 1986-03-27 | 1986-04-30 | Ici Plc | Anti-tumor agents |
| MX173362B (es) * | 1987-03-02 | 1994-02-23 | Pfizer | Compuestos de piperazinil heterociclicos y procedimiento para su preparacion |
| US4925860A (en) | 1987-08-05 | 1990-05-15 | E. I. Du Pont De Nemours And Company | Stable pharmaceutical composition of 3-(hydroxymethyl)-5,5-diphenylhydantoin disodium phosphate ester |
| US4831031A (en) * | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
| GB8809978D0 (en) * | 1988-04-27 | 1988-06-02 | Ici Plc | Anti-tumour agents |
| US5006528A (en) * | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| JP2608788B2 (ja) * | 1988-10-31 | 1997-05-14 | 大塚製薬 株式会社 | 精神分裂病治療剤 |
| DK24089D0 (da) * | 1989-01-20 | 1989-01-20 | Hans Bundgaard | Novel prodrug derivatives of biologically active agents containing hydroxyl groups or nh-acidic groups |
| ES2076253T3 (es) | 1989-05-19 | 1995-11-01 | Hoechst Roussel Pharma | N-(ariloxialquil)-heteroarilpiperidinas y -heteroarilpiperazinas, un procedimiento para su preparacion y su uso como medicamentos. |
| US5350747A (en) * | 1989-07-07 | 1994-09-27 | Pfizer Inc | Heteroaryl piperazine antipsychotic agents |
| FI920023A7 (fi) * | 1989-07-07 | 1992-01-03 | Pfizer | Heteroaryylipiperatsiiniyhdisteet antipsykootteina |
| US5041659A (en) | 1990-04-26 | 1991-08-20 | The Standard Oil Company | Synthesis of n-disubstituted amides by reaction of amides with certain organic hydroxyl compounds |
| DK238190D0 (da) | 1990-10-03 | 1990-10-03 | Lundbeck & Co As H | Depotderivater |
| US5206386A (en) | 1991-03-20 | 1993-04-27 | Isp Investments Inc. | Controlled release N-substituted pyrrolidone esters and process for the use thereof |
| IL101722A (en) | 1991-05-02 | 1996-05-14 | Wyeth John & Brother Ltd | Piperazine derivatives their preparation and pharmaceutical compositions containing them |
| IE914218A1 (en) | 1991-09-11 | 1993-03-24 | Mcneilab Inc | Novel 4-arylpiperazines and 4-arylpiperidines |
| TW226016B (hr) * | 1991-12-30 | 1994-07-01 | Sterling Winthrop Inc | |
| US5462934A (en) * | 1992-03-09 | 1995-10-31 | Takeda Chemical Industries | Condensed heterocyclic ketone derivatives and their use |
| AU4534593A (en) | 1992-06-12 | 1994-01-04 | Affymax Technologies N.V. | Compositions and methods for enhanced drug delivery |
| JP3526575B2 (ja) * | 1993-03-08 | 2004-05-17 | エーザイ株式会社 | ホスホン酸誘導体 |
| US5497763A (en) | 1993-05-21 | 1996-03-12 | Aradigm Corporation | Disposable package for intrapulmonary delivery of aerosolized formulations |
| US5508269A (en) | 1994-10-19 | 1996-04-16 | Pathogenesis Corporation | Aminoglycoside formulation for aerosolization |
| DE4439493A1 (de) | 1994-10-25 | 1996-05-02 | Schering Ag | Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln |
| JP3571795B2 (ja) | 1995-04-18 | 2004-09-29 | 株式会社日本触媒 | Ｎ−（１−アルキルオキシアルキル）カルバメート類の気相分子内脱アルコール反応用触媒およびｎ−ビニルカルバメート類の製造方法 |
| PL189256B1 (pl) * | 1996-03-29 | 2005-07-29 | Duphar Int Res | Związki piperazyny i piperydyny, sposób ich wytwarzania, kompozycja farmaceutyczna zawierająca te związki, zastosowanie tych związków do wytwarzania leków |
| US6083922A (en) | 1996-04-02 | 2000-07-04 | Pathogenesis, Corp. | Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis |
| AU708127B2 (en) | 1996-04-30 | 1999-07-29 | Warner-Lambert Company | Improved process for the synthesis of diesters of phosphoric acid 2,5-dioxo-4,4-diphenyl-imidazolidin-1- ylmethyl ester |
| DE19619819A1 (de) | 1996-05-16 | 1997-11-20 | Boehringer Mannheim Gmbh | Neue Thiazolidindione, Verfahren zu ihrer Herstellung und diese enthaltenden Arzneimittel |
| US5767068A (en) | 1997-02-13 | 1998-06-16 | Pathogenesis Corporation | Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections |
| HUP0001122A3 (en) * | 1997-04-25 | 2002-03-28 | Janssen Pharmaceutica Nv | Farnesyltransferase inhibiting quinazolinones |
| ES2210769T3 (es) * | 1997-06-13 | 2004-07-01 | Cydex Inc. | Compuesto con vida de almacenamiento prolongada que comprende ciclodextrina y medicamentos y promedicamentos que se descomponen en componentes insolubles en agua. |
| AR016384A1 (es) * | 1997-07-30 | 2001-07-04 | Smithkline Beecham Corp | Inhibidores de caspasas, composiciones farmaceuticas que comprenden dichos inhibidores de caspasas y uso de los inhibidores de caspasas para prepararun medicamento util para el tratamiento de apoptosis y desordenes asociados con excesiva actividad de la convertosa il-1 beta. |
| US6180095B1 (en) * | 1997-12-17 | 2001-01-30 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
| ATE261730T1 (de) * | 1997-12-31 | 2004-04-15 | Univ Kansas | Wasserlösliche medikamentenvorstufen tertiärer amine enthaltender medikamente und verfahren zu ihrer herstellung |
| CN1323295A (zh) * | 1998-08-26 | 2001-11-21 | 阿文蒂斯药物有限公司 | 调节细胞粘着抑制作用的氮杂双环化合物 |
| FR2783519B1 (fr) * | 1998-09-23 | 2003-01-24 | Sod Conseils Rech Applic | Nouveaux derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant |
| US6444668B1 (en) * | 1999-05-04 | 2002-09-03 | Wyeth | Combination regimens using progesterone receptor modulators |
| US6509334B1 (en) * | 1999-05-04 | 2003-01-21 | American Home Products Corporation | Cyclocarbamate derivatives as progesterone receptor modulators |
| TWI270545B (en) | 2000-05-24 | 2007-01-11 | Sugen Inc | Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
| CA2433075A1 (en) * | 2001-02-14 | 2002-08-22 | Michael William Wilson | Benzo thiadiazine matrix metalloproteinase inhibitors |
| CA2443350A1 (en) | 2001-04-03 | 2002-12-05 | Aryx Therapeutics | Ultrashort-acting opioids for transdermal application |
| EP2033953A1 (en) * | 2002-02-15 | 2009-03-11 | Glaxo Group Limited | Vanilloid receptor modulators |
| WO2003080047A1 (en) * | 2002-03-20 | 2003-10-02 | Bristol-Myers Squibb Company | Phosphate prodrugs of fluorooxindoles |
| KR101043866B1 (ko) * | 2002-08-20 | 2011-06-22 | 브리스톨-마이어스 스큅 컴퍼니 | 아리피프라졸 복합체 제제 및 방법 |
| MXPA05002007A (es) * | 2002-09-17 | 2005-04-28 | Warner Lambert Co | Piperazinas heterociclicas sustituidas para el tratamiento de la esquizofrenia. |
| EP1556378B1 (en) * | 2002-10-24 | 2008-01-09 | Pfizer Products Inc. | Acyl derivatives of 5-(2-(4-(1,2 benzisothiazole-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one having neuroleptic activity |
| DE10303669A1 (de) | 2003-01-28 | 2004-07-29 | Hans-Knöll-Institut für Naturstoff-Forschung e.V. | Tetraalkylammoniumsalze vom Kohlensäureestertyp, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
| JP2006523237A (ja) | 2003-04-03 | 2006-10-12 | セマフォア ファーマシューティカルズ， インコーポレイテッド | Ｐｉ−３キナーゼインヒビタープロドラッグ |
| AU2004243096B2 (en) * | 2003-05-23 | 2008-12-18 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives and mood stabilizers for treating mood disorders |
| US20050032811A1 (en) * | 2003-08-06 | 2005-02-10 | Josiah Brown | Methods for administering aripiprazole |
| US7160888B2 (en) | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
| WO2005066165A1 (en) | 2003-12-31 | 2005-07-21 | Warner-Lambert Company Llc | N-substituted piperidine and piperazine derivatives |
| MY144177A (en) * | 2004-02-04 | 2011-08-15 | Novartis Ag | Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide. |
| RU2006129307A (ru) | 2004-02-13 | 2008-02-20 | Пфайзер Продактс Инк. (Us) | Терапевтические комбинации атипичных нейролептиков с антагонистами кортикотропин-рилизинг фактора |
| US7169803B2 (en) * | 2004-03-15 | 2007-01-30 | Bristol-Myers Squibb Company | N-substituted prodrugs of fluorooxindoles |
| EP1732929B1 (en) * | 2004-03-23 | 2010-10-20 | Nissan Chemical Industries, Ltd. | Tricyclic benzopyran compound as anti-arrhythmic agents |
| US7119214B2 (en) * | 2004-04-13 | 2006-10-10 | Cephalon France | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives |
| WO2006037090A2 (en) | 2004-09-28 | 2006-04-06 | Purdue Research Foundation | Drug-phosphate conjugates as prodrugs |
| WO2006090273A2 (en) | 2005-02-22 | 2006-08-31 | Warner-Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia |
| TWI320783B (en) | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
| EP1777222A1 (en) * | 2005-09-22 | 2007-04-25 | Galantos Pharma GmbH | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
| CN101300256A (zh) | 2005-10-31 | 2008-11-05 | 辉瑞产品公司 | 7-[4-(4-萘-1-基-哌嗪-1-基)-丁氧基]-3,4-二氢-1h-[1,8]萘啶-2-酮的结晶盐 |
| WO2007059111A2 (en) | 2005-11-14 | 2007-05-24 | Entremed, Inc. | Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents |
| EA200801716A1 (ru) * | 2006-01-18 | 2009-04-28 | Амген Инк. | Тиазольные соединения и их применение |
| TW200804359A (en) * | 2006-01-19 | 2008-01-16 | Speedel Experimenta Ag | Substituted 4-phenylpiperidines |
| JP2010501625A (ja) | 2006-08-31 | 2010-01-21 | ソルベイ・フアーマシユーチカルズ・ベー・ブイ | 統合失調症を処置するためのビフェプルノックスの滴定スケジュールおよびそれにおける使用のためのキット |
| US20090068290A1 (en) * | 2006-08-31 | 2009-03-12 | Michel Bourin | Bifeprunox doses for treating schizophrenia |
| WO2008034041A2 (en) * | 2006-09-15 | 2008-03-20 | Astrazeneca Ab | Therapeutic combinations |
| CN101678120A (zh) * | 2006-12-05 | 2010-03-24 | 纽罗吉斯克斯公司 | 前药及其制备和使用方法 |
| US20080312199A1 (en) * | 2006-12-15 | 2008-12-18 | Glinsky Gennadi V | Treatments of therapy resistant diseases and drug combinations for treating the same |
| TWI325694B (en) * | 2006-12-15 | 2010-06-01 | Ind Tech Res Inst | All digital delay locked loop |
| US20080186971A1 (en) * | 2007-02-02 | 2008-08-07 | Tarari, Inc. | Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic |
| US20090053329A1 (en) * | 2007-03-19 | 2009-02-26 | Acadia Pharmaceuticals, Inc. | Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics |
| PT2142529E (pt) | 2007-04-27 | 2014-03-20 | Purdue Pharma Lp | Antagonistas de trpv1 e as respectivas utilizações |
| AU2008254585B2 (en) | 2007-05-21 | 2013-09-26 | Reviva Pharmaceuticals, Inc. | Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents |
| TW200904446A (en) | 2007-05-30 | 2009-02-01 | Wyeth Corp | Antidepressant heteroaryl derivatives of heterocycle-fused benzodioxans |
| WO2009003136A1 (en) * | 2007-06-26 | 2008-12-31 | Rigel Pharmaceuticals, Inc. | Substituted pyrimidine-2, 4 -diamines for treating cell proliferative disorders |
| US20100292316A1 (en) * | 2007-07-18 | 2010-11-18 | Research Development Foundation | Improved therapeutic methods and compositions comprising chroman ring compounds |
| US8076334B2 (en) * | 2007-09-20 | 2011-12-13 | Hoffmann-La Roche Inc. | Prodrugs of thyroid hormone analogs |
| WO2009052467A1 (en) | 2007-10-19 | 2009-04-23 | Board Of Regents Of The University Of Texas System | Methods of identifying pi-3-kinase inhibitor resistance |
| SG2014005318A (en) * | 2009-01-23 | 2014-03-28 | Rigel Pharmaceuticals Inc | Compositions and methods for inhibition of the jak pathway |
| US9307454B2 (en) * | 2009-02-09 | 2016-04-05 | Qualcomm Incorporated | Method and apparatus for maintaining location continuity for a UE following handover |
| WO2010151689A1 (en) | 2009-06-25 | 2010-12-29 | Alkermes, Inc. | Heterocyclic compounds for the treatment of neurological and psychological disorders |
| AU2010266040B2 (en) | 2009-06-25 | 2015-01-15 | Alkermes Pharma Ireland Limited | Prodrugs of NH-acidic compounds |
| JP5456891B2 (ja) * | 2009-06-26 | 2014-04-02 | ノバルティス アーゲー | Ｃｙｐ１７阻害剤としての１，３−二置換イミダゾリジン−２−オン誘導体 |
| US20110166128A1 (en) * | 2010-01-07 | 2011-07-07 | Alkermes, Inc. | Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders |
| EP2521545B1 (en) | 2010-01-07 | 2019-11-27 | Alkermes Pharma Ireland Limited | Prodrugs of heteroaromatic compounds |
| WO2011084851A1 (en) * | 2010-01-07 | 2011-07-14 | Alkermes, Inc. | Asenapine produrugs |
| ES2647361T3 (es) | 2010-01-07 | 2017-12-21 | Alkermes Pharma Ireland Limited | Profármacos de sales de amonio cuaternario |
| US20110166156A1 (en) * | 2010-01-07 | 2011-07-07 | Alkermes, Inc. | Prodrugs for the Treatment of Schizophrenia and Bipolar Disease |
| CA2797708C (en) * | 2010-05-04 | 2016-08-16 | Alkermes Pharma Ireland Limited | Process for synthesizing oxidized lactam compounds |
| CN102260290A (zh) | 2010-05-25 | 2011-11-30 | 苏州波锐生物医药科技有限公司 | 喹喏啉酮类化合物及其在制备精神病药物中的用途 |
| US8530413B2 (en) * | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| EP2585066B1 (en) * | 2010-06-24 | 2018-09-26 | Alkermes Pharma Ireland Limited | Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
| EP2608670B1 (en) * | 2010-08-23 | 2018-10-31 | Alkermes Pharma Ireland Limited | Methods for treating antipsychotic-induced weight gain |
| ES2661574T3 (es) * | 2010-12-23 | 2018-04-02 | Alkermes Pharma Ireland Limited | Profármacos de carga de múltiples PAF |
| LT2685979T (lt) * | 2011-03-18 | 2016-12-12 | Alkermes Pharma Ireland Limited | Injekcinės farmacinės kompozicijos, apimančios vandenyje netirpų antipsichotiką, sorbitano lauratą ir polisorbatą 20 |
| ES2715562T3 (es) | 2011-12-15 | 2019-06-04 | Alkermes Pharma Ireland Ltd | Profármacos de compuestos de amina secundaria |
| NZ630643A (en) * | 2012-03-19 | 2017-08-25 | Alkermes Pharma Ireland Ltd | Pharmaceutical compositions comprising fatty acid esters |
| NZ630703A (en) * | 2012-03-19 | 2017-02-24 | Alkermes Pharma Ireland Ltd | Pharmaceutical compositions comprising glycerol esters |
| EP2827866B1 (en) * | 2012-03-19 | 2023-05-03 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising benzyl alcohol |
| WO2014080285A2 (en) * | 2012-09-19 | 2014-05-30 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions having improved storage stability |
| DK2970101T3 (en) | 2013-03-14 | 2018-08-20 | Alkermes Pharma Ireland Ltd | PRO-DRUGS OF FUMARATES AND THEIR USE IN TREATING DIFFERENT DISEASES |
| US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
| US10525057B2 (en) * | 2013-09-24 | 2020-01-07 | Otsuka Pharmaceutical Co., Ltd. | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
| CN106132415A (zh) * | 2014-03-20 | 2016-11-16 | 奥克梅斯制药爱尔兰有限公司 | 具有增加的注射速度的阿立哌唑制剂 |
| US10016415B2 (en) * | 2014-08-18 | 2018-07-10 | Alkermes Pharma Ireland Limited | Aripiprazole prodrug compositions |
| ES2893973T3 (es) * | 2016-02-17 | 2022-02-10 | Alkermes Pharma Ireland Ltd | Composiciones de múltiples profármacos de aripiprazol |
-
2010
- 2010-06-24 WO PCT/US2010/039855 patent/WO2010151689A1/en active Application Filing
- 2010-06-24 SI SI201031536T patent/SI2445502T1/sl unknown
- 2010-06-24 LT LTEP10792677.6T patent/LT2445502T/lt unknown
- 2010-06-24 HU HUE10792677A patent/HUE033442T2/en unknown
- 2010-06-24 DK DK10792677.6T patent/DK2445502T4/da active
- 2010-06-24 NZ NZ597107A patent/NZ597107A/en unknown
- 2010-06-24 CA CA2766088A patent/CA2766088C/en active Active
- 2010-06-24 EP EP22195630.3A patent/EP4124616A1/en active Pending
- 2010-06-24 EP EP10792677.6A patent/EP2445502B2/en active Active
- 2010-06-24 SM SM20170430T patent/SMT201700430T1/it unknown
- 2010-06-24 HR HRP20171415TT patent/HRP20171415T4/hr unknown
- 2010-06-24 EP EP17176623.1A patent/EP3309151B1/en active Active
- 2010-06-24 ES ES17176623T patent/ES3031438T3/es active Active
- 2010-06-24 RS RS20170927A patent/RS56352B2/sr unknown
- 2010-06-24 PL PL10792677.6T patent/PL2445502T5/pl unknown
- 2010-06-24 ES ES10792677T patent/ES2639065T5/es active Active
- 2010-06-24 US US12/823,007 patent/US8431576B2/en active Active
- 2010-06-24 FI FIEP10792677.6T patent/FI2445502T4/fi active
- 2010-06-24 PT PT107926776T patent/PT2445502T/pt unknown
- 2010-06-24 JP JP2012517738A patent/JP5733841B2/ja active Active
- 2010-06-24 AU AU2010266018A patent/AU2010266018B2/en active Active
-
2012
- 2012-09-07 US US13/607,066 patent/US8796276B2/en active Active
-
2014
- 2014-06-05 US US14/297,195 patent/US20140350254A1/en not_active Abandoned
- 2014-12-26 JP JP2014264706A patent/JP6093341B2/ja active Active
-
2015
- 2015-04-02 US US14/677,333 patent/US20150274670A1/en not_active Abandoned
-
2016
- 2016-05-05 US US15/147,021 patent/US10023537B2/en active Active
- 2016-12-02 JP JP2016235293A patent/JP6546896B2/ja active Active
-
2017
- 2017-09-13 CY CY20171100963T patent/CY1120054T1/el unknown
-
2018
- 2018-01-19 US US15/875,478 patent/US10112903B2/en active Active
- 2018-09-14 US US16/131,773 patent/US10351529B2/en active Active
- 2018-09-27 HK HK18112426.9A patent/HK1253046A1/en unknown
-
2019
- 2019-05-29 US US16/425,119 patent/US10822306B2/en active Active
- 2019-06-24 JP JP2019116369A patent/JP7042239B2/ja active Active
-
2020
- 2020-09-14 US US17/020,499 patent/US11518745B2/en active Active
-
2022
- 2022-10-31 US US18/051,216 patent/US12180164B2/en active Active
-
2024
- 2024-11-14 US US18/948,416 patent/US20250214940A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171415T4 (hr) | Heterociklični spojevi za liječenje neuroloških i psiholoških poremećaja | |
| PE20251288A1 (es) | Compuestos heterociclicos como inmunomoduladores | |
| HRP20130738T1 (hr) | Postupak lijeäśenja ili profilakse | |
| EA200901159A1 (ru) | Производные 3-циано-4-(4-фенилпиперидин-1-ил)пиридин-2-она | |
| EA200901162A1 (ru) | Производные 1,4-дизамещённого 3-цианопиридона и их применение в качестве положительных модуляторов рецептора mglur2 | |
| HRP20120695T1 (hr) | 8-supstituirani benzoazepini kao modulatori toll-u sličnog receptora | |
| ATE549334T1 (de) | 7,8-dihydro-1,6-naphthyridin-5(6h)-one und verwandte bicyclische verbindungen als hemmer der dipeptidyl-peptidase iv sowie verfahren | |
| RU2014141579A (ru) | Гетероциклические соединения в качестве ингибиторов бета-лактамаз | |
| BR0104228A (pt) | Derivados do ácido de alquilamino úteis como agentes farmacêuticos, método para fabricação de um composto, composição farmacêutica, métodos para tratamentos diversos e uso de um composto na fabricação de um medicamento para tratamentos diversos | |
| JP2008526999A5 (hr) | ||
| MX2012001399A (es) | Profarmacos que comprenden un conjugado de insulina-conector. | |
| NO20073357L (no) | 5-karboksamid substituerte tiazol derivater som reagerer med ionekanaler, i saerdeleshet med ionekanaler fra Kv familien | |
| HK1254129A1 (zh) | 給予谷氨酰胺酶抑制劑的方法 | |
| RU2009136592A (ru) | Терапевтические агенты | |
| AR063256A1 (es) | Derivados de 4, 5, 6, 7-tetrahidro-imidazo[4, 5, 1-jk][1]benzacepin-2(1h)-ona, una composicion farmaceutica y un aditivo de pienso que los comprenden y el uso de los mismos como medicamento para el tratamiento de enfermedades mediadas por agonistas del adrenoreceptor beta-2. | |
| KR900015729A (ko) | 흥분성 아미노산 길항제 | |
| MA30315B1 (fr) | Derives de 1,2,4,5-tetrahydro-3h-benzazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| PH12021552201A1 (en) | Benzodiazepine derivatives as rsv inhibitors | |
| MA38854A1 (fr) | Dérivés amides utilisés en tant qu'antagonistes des récepteurs de l'acide lysophosphatidique | |
| AR051940A1 (es) | Compuestos y metodos para modular la actividad de la trombopoyetina | |
| EA201992127A1 (ru) | ФАРМАКОЛОГИЧЕСКИ АКТИВНЫЕ АЛИЦИКЛИЧЕСКИ ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА | |
| RU2008127260A (ru) | Производные хиназолинона в качестве антагонистов ваниллоидов | |
| AU2023241042A1 (en) | Compositions and methods for treating cancer | |
| ATE487690T1 (de) | 2-aminobicyclo 3.1.0 hexan-2,6- dicarbonsäureesterderivat | |
| CN115175887A (zh) | 苯酚衍生物及其在医药上的应用 |